Comparative Pharmacology
Head-to-head clinical analysis: HYPAQUE CYSTO versus IOPAMIDOL 200.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYPAQUE CYSTO versus IOPAMIDOL 200.
HYPAQUE-CYSTO vs IOPAMIDOL-200
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
HYPAQUE-CYSTO (diatrizoate meglumine) is a radiopaque contrast agent that absorbs x-rays, providing contrast in radiographic imaging. It acts as an iodinated contrast medium.
Iopamidol is a nonionic iodinated contrast agent that attenuates X-rays, enhancing vascular and tissue contrast. It does not have a pharmacological effect but provides radiographic opacity.
Intravesical instillation: 100-300 mL of 30% solution for retrograde cystourethrography; single administration.
Intravascular: 50-150 mL (75-225 mg iodine/kg) IV; frequency depends on procedure, usually single dose. Intrathecal: 5-15 mL (200 mg iodine/mL) injected into subarachnoid space.
None Documented
None Documented
Terminal elimination half-life: 1.5–2.5 hours (normal renal function). Prolonged in renal impairment.
Terminal half-life: 2 hours (normal renal function); prolonged to 8-48 hours in severe renal impairment (CrCl <30 mL/min).
Renal excretion via glomerular filtration: >95% unchanged within 24 hours. Fecal excretion: <5%.
Renal: >95% unchanged via glomerular filtration within 24 hours; biliary/fecal: <1%.
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent